SOLICITATION NOTICE
B -- Deep Sequencing and Microarray Core
- Notice Date
- 8/4/2011
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-CSB-(HL)-2011-284-DDC
- Archive Date
- 8/24/2011
- Point of Contact
- Deborah - Coulter, Phone: (301) 435-0368
- E-Mail Address
-
dc143b@nih.gov
(dc143b@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Heart, Lung, and Blood Institute (NHLBI) does not intend to award a contract on the basis of responses nor otherwise pay for the preparation of any information submitted. As a result of this Sources Sought notice, the NHLBI may issue a Request for Quote (RFQ). The reference number: NHLBI-CSB-(HL)-2011-193-DDC. Background The National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), Cardiovascular and Pulmonary Branch, developed cell lines from patients with Lymphangioleiomyomatosis (LAM), a devastating lung disease of women. The cell lines developed are being used to understand the pathogenesis of this disease. A critical aspect for the understanding of the disease is to obtain information about the cells gene expression when treated with estrogen. We are also interested on determining the role of mutations in the tumor suppressor gene (Tuberous Sclerosis Complex 2) because it affects development of Lymphangioleiomyomatosis (LAM) which is a disease studied in this laboratory. This aspect is important because of the prevalence of LAM in women. We have studied many candidate genes involved in LAM but we cannot get a full understanding of the disease. Thus, we would prefer to obtain a more global idea of the gene expression changes of these cells. Therefore, we would need to carry out gene expression profiles of cells non-treated or treated with estrogen. These experiments are essential for the goals of the branch. Purpose and Objectives: The main of objective of this requirement is to carry out gene expression profiles that would allow us to obtain data that will tell us differences of the genes present in each sample when treated with estrogens. The work will involve following services on the below samples: -Isolation of RNA from cells cultured in vitro. -Labeling of the RNA -Analysis of the molecules 1. Processing 40 Human samples on Illumina HT-12 beads arrays 2. Processing 48 18 mouse samples on Illumina WG-6 beads arrays 3. Processing 48 human samples on Illumina HT-12 beads arrays 4. Processing 24 mouse samples on Illumina WG-6 beads arrays The Government's estimated delivery time is 6 weeks from the time of sample shipment. The sole source determination is based on the fact John Hopkins Medical Institute (JHMI) Deep Sequencing and microarray core provides services to process microarrays that allow screening of multiple genes for the purpose of studying gene expression of cell lines treated with estrogens. The service of processing the arrays would allow the Government to determine studies of high quality using a reliable platform. JHMI facility is unique because it isolates the RNA from frozen cell lines provided by NIH. As part of the services they provide the chips used for the assay. Therefore it is not in the best interest for the Government to change Platform at this time. This could cause a delay in the research. The notice of intent is not a request for competitive proposals. Only one responsible source and no other supplies or services will satisfy agency requirements. Industry Classification (NAICS) Code is 541711, Research and Development in Biotechnology with size standard of 500 employees; the small business set-aside does not apply for this requirement. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001) and the resultant purchase order will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-53 (August 4, 2011). This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis, by August 9, 2011, 7:30 am Eastern Standard Time. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurement. Inquires to this announcement, referencing synopsis number NHLBI-CSB-(HL)-2011-284-DDC, may be submitted to the National Heart, Lung and Blood Institute, Office of Acquisition, Procurement Branch, 6701 Rockledge Drive, Suite 6042, Bethesda, Maryland 20892-7902, Attention: Deborah Coulter. Response may be submitted electronically to coulterd@nhlbi.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-(HL)-2011-284-DDC/listing.html)
- Place of Performance
- Address: NIH, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN02522417-W 20110806/110804235553-136bd5b5a0fe02db64a3b1d4f411301a (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |